Abstract: The present invention relates to an RGD motif-containing peptide or a fragment thereof, which is used to effectively treat burns and glaucoma, obtain an excellent effect of alleviating skin wrinkles, and is effective in the promotion of hair restoration and hair growth as well as the prevention of hair loss. Therefore, the motif-containing peptide or the fragment thereof can be utilized for a cosmetic composition and a pharmaceutical composition.

Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.

Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.

Abstract: Embodiments herein relate to compositions and methods for stabilizing live alphaviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated alphaviruses. Certain embodiments relate to providing a stabilizing composition while reducing immune reaction in a subject to excipients that stabilize the live alphaviruses by providing improved formulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable applications and methods wherein the compositions reduce degradation of the live alphaviruses.

Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described.

Abstract: A novel method for preventing or treating an infectious disease in a subject in need thereof. In particular the method includes the administration of a combination, pharmaceutical combination, medicament or kit-of-parts having a first part including a CD8 vaccine specific for at least one infectious disease-related antigen, a second part including an agent neutralizing circulating alpha interferon and/or an agent blocking interferon alpha signaling, and/or a third part including a type III interferon and/or an agent stimulating the production of type III interferon.

Abstract: Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.

Abstract: The disclosure concerns compositions containing inactivated but therapeutically active biopharmaceuticals, and methods for formulation thereof. Biopharmaceuticals are encapsulated and immobilized in dry amorphous carbohydrate-glass and irradiated for inactivation while in the dry state. The resulting compositions provide ambient-temperature stable, therapeutically active but inactivated biopharmaceuticals for use in vaccines and other applications.

Abstract: Provided herein are compositions, combinations, and methods comprising Canine Respiratory Coronavirus (CRCoV), which are effective in treating or preventing respiratory infections associated secondary pathogens, such as Bordetella bronchiseptica, in animals.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1. L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Abstract: A pharmaceutical device for electric-field assisted administration of Tapentadol and/or of a physiologically acceptable salt thereof, the device comprising at least one pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a and/or 1b and 2b), optionally at least one additional electrode as an auxiliary electrode, at least one drug reservoir (3) containing at least a portion of the Tapentadol and/or a physiologically acceptable salt thereof, and means (4) for applying the device to skin (5).

Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.

Abstract: Compositions comprising a fluorescein component and benoxinate component and the corresponding uses of these compositions are described herein. These compositions have improved storage life and the fluorescein component and/or benoxinate component minimally degrade after 12 to 18 months of storage.

Abstract: A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus® and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.

Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: The present invention provides immediate release abuse resistant or deterrent formulations such as ingestible dosage form articles suitable for the delivery of one or more medicaments or other active materials.

Abstract: The present invention relates to compositions providing improved preservative efficacy. The present invention further relates to polyquaternium compound containing compositions having improved the antifungal activity. In certain embodiments, the present invention relates to ophthalmic compositions comprising a polyquaternium compound, a polyol or combination of polyols, borate compound, and an antimicrobial mixture comprising electrolytes and nutrients.

Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Abstract: The present invention provides a peptide composition that can achieve both excellent storage stability and transparency. The peptide composition of the present invention includes: a self-assembling peptide; a buffering agent having a pKa of 3.5 or more and less than 7.5 and containing one or more nitrogen atoms; and water, and has a pH of from 4.5 to 6.6.

Abstract: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.

Abstract: The invention generally relates to zwitterionic polymers (including zwitterionic copolymers), such as polymethacrylic structures, with pendent functional moieties, such as therapeutic or biologic moieties. More particularly, the invention relates to phosphorylcholine-substituted methacrylic polymers prepared by free radical polymerization and click chemistry, for example, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as biological or therapeutic agents and in drug delivery thereof.

Abstract: The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices.

Abstract: This present application relates to a drug delivery method. In particular, the present invention discloses a non-invasive drug delivery method using Listeria adhesion protein (LAP) an analogue, or a fragment thereof. Incorporation of those peptides or a fragment thereof, either by a physical mixture of a pharmaceutical formulation or as a covalent construction at a molecular level or nanoscale is within the scope of this disclosure.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

Abstract: Methods for treating age-related eye diseases or conditions are provided. Methods for treating an age-related eye disease or condition in a subject by administering one or more demethylation compounds or agents are provided.

Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.

Abstract: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site.

Abstract: A light source for emitting emitted light having an SPD comprising: (a) a plurality of light emitters including at least one violet solid-state emitter; (b) at least one phosphor; wherein said light emitters and said at least one phosphor being configured such that: at least 25% of the power within the SPD is in the range 390-420 nm, and the emitted light has a chromaticity which is within a Duv distance of less than 5 points from the Planckian locus.

Abstract: Described are a device and a method for rapidly sterilizing liquid nitrogen in a container using ultraviolet radiation irradiated for a predetermined length of time based on the temperature measured by a sensor and on the minimum dose of radiation necessary to kill micro-organisms resistant to liquid nitrogen.

Abstract: The multifunction LED lighting apparatus of the present invention includes at least one lighting LED, at least one ultraviolet (UV) LED, a substrate configured to have the at least one lighting LED and the at least one UV LED mounted thereon, and a cover disposed to face the substrate at a specific interval and configured to cover the lighting LED and the UV LED. The at least one lighting LED and the at least one UV LED are integrally mounted on the substrate and configured to form a single module of a thin sheet form, and the cover is installed to cover and support the single module placed on the inside wall of an application.

Abstract: A device for rapidly sanitizing a surface is described. The device has an enclosure having an opening adapted to insert a surface, and an interior; a liquid nitric oxide solution applicator; and an absorbent material. The liquid nitric oxide solution applicator is in fluid communication with the interior of the enclosure and is adapted to apply liquid nitric oxide solution onto the surface when the surface is positioned within the enclosure. A method of rapidly sanitizing a surface is described. The devices and methods provided herein may be implemented to sanitize the surface of any body part or item that may be placed within the device. An infectious agent on the surface may be killed; i.e., the surface is disinfected. Non-limiting applications of the devices and methods include preventing nosocomial infections or food contamination, sanitizing household items, and implementing sanitizing procedures to comply with FDA Good Manufacturing Practices.

Abstract: A method of treating a substance in the form of divided solids, includes the steps of introducing the substance into an enclosure in which there exists an ozonated atmosphere under pressure, conveying the substance in the enclosure with a continuous movement in such a manner that the substance is located continuously in the ozonated atmosphere while it is being conveyed in the enclosure, the substance being conveyed by vibration means causing the enclosure to vibrate, and unloading the substance from the enclosure via the outlet after a single passage of the substance through the enclosure.

Abstract: The invention relates to a sterilizers and methods of sterilization of an instrument. The sterilizer includes an ozone generator, an air mover, an oxygen concentrator, and a controller. The ozone generator, which is housed by the sterilization chamber, generates at least one plasma field. The air mover circulates air through the sterilization chamber. The oxygen concentrator delivers oxygen-concentrated air to the sterilization chamber. The controller communicates with the ozone generator, the air mover, and the oxygen concentrator. The sterilizer may also include a battery to power the components of the sterilizer. A portable case may house the sterilizer.

Abstract: A biological indicator with variable resistance may be controlled by moving a cap or housing of the biological indicator to cause the size of vents that allow flow of sterilant through the housing to decrease or increase in effective size. An indicator window may show a user the current resistance of the biological indicator, and may also show a readable indicator that may be captured by a scanner to allow a sterilizing cabinet to identify the current resistance. When the level of resistance shown by the readable indicator is not compatible with a sterilization cycle selected by a user, the procedure may be delayed and a notification provided to the user that a problem exists. The readable indicator may be a passive tag with a memory that allows information to be read and written, so that the biological indicator may carry data from one device to another.

Abstract: A freshening composition is provided. The freshening composition includes about 0.02 wt. % to about 1.0 wt. %, based on the weight of the composition, of a sulfur-containing pro-perfume. The freshening composition further includes about 0.2 wt. % to about 1.4 wt. %, based on the weight of the composition, of a perfume mixture, the perfume mixture comprising at least one perfume material selected from the group consisting of: 3-(1,3-Benzodioxol-5-yl)-2-methylpropanal, canthoxal, vanillin, ethyl vanillin, citral, ligustral, cinnamic aldehydes, and combinations thereof. The freshening composition also includes a carrier.

Abstract: The present invention is directed to a digital aroma system that provides a scented air on demand to various devices in various forms and user held devices including: remote controls and mobile computing devices. Dry fragrance infused substrates are contained in fragrance cartridges that are removably mounted in a cassette that is connected to a manifold that has airway passages that are connected to fans or pumps that are controlled by a computer processor. In response to a fragrance control signal, the processor can selectively direct scented air having a specified fragrance to a system user.

Abstract: A substrate includes a double-network polymer system including a cross-linked, covalently-bonded polymer and a reversible, partially ionicly-bonded polymer, wherein the substrate has a moisture level less than or equal to 15 percent of the total weight of the substrate, and wherein the substrate includes a latent retractive force. A method for manufacturing a substrate includes producing a double-network hydrogel including a cross-linked, covalently-bonded polymer and a reversible, ionicly-bonded polymer; elongating by force the double-network hydrogel in at least one direction; dehydrating while still elongated the double-network hydrogel to form a substantially-dehydrated double-network polymer system; and releasing the force to produce the substrate.

Abstract: An absorbent wound care device includes two or more materials which individually do not gel when exposed to a fluid but do gel when brought together and exposed to a fluid. The device is particularly intended for haemostatic use and for absorbing bodily fluids being emitted from wounds and physiological target sites.

Abstract: Materials and methods for immobilizing bioactive molecules, stem and other precursor cells, and other agents of therapeutic value in surgical sutures and other tissue scaffold devices are described herein. Broadly drawn to the integration and incorporation of bioactive materials into suture constructs, tissue scaffolds and medical devices, the present invention has particular utility in the development of novel systems that enable medical personnel performing surgical and other medical procedures to utilize and subsequently reintroduce bioactive materials extracted from a patient (or their allogenic equivalents) to a wound or target surgical site.

Abstract: Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

Abstract: A discovery of the conversion of amorphous calcium polyphosphate (ACPP) or/and other polyphosphate salts with various type of calcium phosphate to new calcium phosphate product (i.e. dicalcium phosphate dihydrate (DCPD)) in a liquid environment. The discovery includes mixing a various type of calcium phosphate with an aqueous ACPP or/and other polyphosphate salts gel, which is fast setting and possessing strong mechanical strength, and can be gradually converted to DCPD/hydroxyapatites in physiological condition. This injectable past can be applied as alternative of conventional CPC bone cement that is suitable for bone void repair due to its excellent properties in osteoconductivity and osseointegration. It can also be applied as drug delivery device in tissue engineering for its strong bonding to drug molecules.

Abstract: Non-woven graft materials for use in specialized surgical procedures such as neurosurgical procedures, methods for making the non-woven graft materials, and methods for repairing tissue such as neurological tissue using the non-woven graft materials are disclosed. More particularly, disclosed are non-woven graft materials including at least two distinct fiber compositions composed of different polymeric materials, methods for making the non-woven graft materials and methods for repairing tissue in an individual in need thereof using the non-woven graft materials.

Abstract: The present invention relates generally to methods and materials for use in the production of implants, particularly luminal tissue implants, where the implants are engineered by seeding of an acellular scaffold or matrix with muscle cell precursors and fibroblasts, for example injection seeding using particular ratios of cells. The present invention provides methods for producing tissue engineered constructs for implantation into a subject which can utilise novel seeding processes described herein for improved cell engraftment and differentiation. In addition, the invention describes methods for treating an individual by implantation of the engineered constructs or tissues of the invention.

Abstract: Provided is an implant configured to fit at or near a bone defect to promote bone growth, the implant comprising: a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and an oxysterol in an amount of about 20 wt % to about 90 wt % of the implant. The implant has a high oxysterol load. Methods of making and use are further provided.